<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary arteriovenous malformations: Clinical features and diagnostic evaluation in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Justin McWilliams, MD, FSIR</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nestor L Muller, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary arteriovenous malformations (PAVMs) are abnormal communications between pulmonary arteries and veins [<a href="#rid1">1</a>]. Alternative names include pulmonary arteriovenous fistulae, pulmonary arteriovenous aneurysms, cavernous angiomas of the lung, and pulmonary telangiectases [<a href="#rid2">2</a>]. PAVMs are uncommon, but they are an important consideration in the differential diagnosis of common pulmonary problems, including dyspnea, hemoptysis, hypoxemia, and pulmonary nodules.</p><p>Clinical features, indications for diagnostic testing, and an approach to the diagnostic evaluation of suspected PAVMs are reviewed here. The epidemiology, etiology, pathology, and treatment of PAVMs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">"Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a>.)</p><p class="headingAnchor" id="H259347582"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Although the literature prior to 2000 [<a href="#rid3">3</a>] suggested that most PAVMs were associated with pulmonary symptoms, studies since 2000 describe pulmonary symptoms in only 20 to 65 percent (approximately 40 percent) and the remainder are asymptomatic, typically found incidentally on chest imaging or during screening of patients with known or suspected hereditary hemorrhagic telangiectasia (HHT) [<a href="#rid4">4-8</a>]. The most common pulmonary symptoms are dyspnea in 13 to 56 percent and hemoptysis in 7 to 30 percent  (<a class="graphic graphic_table graphicRef79966" href="/z/d/graphic/79966.html" rel="external">table 1</a>) [<a href="#rid4">4,5,8,9</a>]. Patients with underlying HHT (which is the most common cause of PAVMs), often show symptoms attributable to this disorder including epistaxis and mucocutaneous telangiectases  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 2</a>). In addition, PAVMs should always be suspected in patients who present with unexplained dyspnea or hypoxemia as well as in patients with nodules and a history of a stroke or brain abscess (stroke and brain abscess are common complications of PAVMs). (See <a class="local">'Features attributable to PAVM'</a> below and <a class="local">'Features attributable to HHT'</a> below and <a class="local">'Features attributable to PAVM complications'</a> below and  <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">"Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults", section on 'Etiology'</a>.)</p><p>Symptoms related to PAVMs typically begin during the fourth through sixth decades of life [<a href="#rid10">10</a>], whereas symptoms of HHT frequently develop before the age of 20 years (eg, epistaxis due to nasal telangiectases or appearance of telangiectases on the skin and lips  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 2</a>)) [<a href="#rid11">11,12</a>].</p><p>The frequency and severity of symptoms tend to be greater among those who have larger PAVMs, multiple PAVMs, a higher shunt fraction, or HHT, although not all studies have found this [<a href="#rid13">13-16</a>]. Diffuse microvascular PAVMs are almost always symptomatic  (<a class="graphic graphic_diagnosticimage graphicRef102814" href="/z/d/graphic/102814.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef102815" href="/z/d/graphic/102815.html" rel="external">image 2</a>) [<a href="#rid17">17</a>].</p><p>When compared with patients with HHT, patients with idiopathic PAVMs are expected to present with similar manifestations and complications (eg, dyspnea and stroke) except for a lesser incidence of epistaxis, telangiectases, and multiple PAVMs [<a href="#rid18">18</a>]. Two retrospective studies totaling 118 patients demonstrated that non-HHT PAVMs have a higher female predominance (60 to 73 percent), are more often solitary (83 to 90 percent), and are often symptomatic with a high rate of neurologic complications [<a href="#rid19">19,20</a>]. The causes of PAVMs are presented in the table  (<a class="graphic graphic_table graphicRef102807" href="/z/d/graphic/102807.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">"Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults"</a>.)</p><p class="headingAnchor" id="H259347921"><span class="h2">Features attributable to PAVM</span></p><p class="headingAnchor" id="H111281836"><span class="h3">Dyspnea</span><span class="headingEndMark"> — </span>Dyspnea is the most common complaint directly attributable to PAVMs  (<a class="graphic graphic_table graphicRef79966" href="/z/d/graphic/79966.html" rel="external">table 1</a>). Older retrospective series report about half of patients with PAVMs have dyspnea [<a href="#rid4">4,18</a>]. However, with the increased use of computed tomography (CT) particularly in patients with HHT, the detection of smaller PAVMs may have reduced the frequency of this symptom with case series published since 2006 reporting dyspnea in 13 to 56 percent [<a href="#rid4">4,5,8,9,13,18,21</a>]. In a study of 202 patients with HHT and PAVM, 44 percent had dyspnea [<a href="#rid21">21</a>]. However, HHT patients with or without PAVM frequently had other causes of dyspnea such as asthma or anemia [<a href="#rid21">21</a>]. Dyspnea is especially common among patients with clubbing and among patients whose PAVMs are large, multiple, bilateral, or diffuse [<a href="#rid3">3</a>]. It may occasionally be caused by high output heart failure due to hepatic AVM or severe anemia due to bleeding in patients with HHT (ie, extrapulmonary shunts) [<a href="#rid22">22</a>]. The mechanism of dyspnea is unclear but may relate to hypoxemia from shunt or airflow limitation [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia"</a>.)</p><p class="headingAnchor" id="H111281868"><span class="h3">Hemoptysis</span><span class="headingEndMark"> — </span>Hemoptysis, presumably due to endobronchial or intraparenchymal PAVM rupture, occurs in 7 to 30 percent of patients with PAVM  (<a class="graphic graphic_table graphicRef79966" href="/z/d/graphic/79966.html" rel="external">table 1</a>) [<a href="#rid4">4,8,9</a>]. Hemoptysis may be massive with the potential to be life-threatening especially during pregnancy, the details of which are discussed separately. Hemoptysis in PAVM patients should be taken seriously as it may sometimes be a sign of an impending and life threatening rupture. (See <a class="local">'Hemothorax and hemoptysis'</a> below and  <a class="medical medical_review" href="/z/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Pulmonary AVMs'</a> and  <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a>.)</p><p class="headingAnchor" id="H111281882"><span class="h3">Platypnea and orthodeoxia</span><span class="headingEndMark"> — </span>Platypnea is dyspnea that is induced by the upright position and relieved by recumbency; it is believed to be the result of increased blood flow through PAVMs in the dependent portions of the lungs upon assuming the upright position. Platypnea is a classic but rare symptom in patients with PAVMs. As an example, in one eight-year prospective series of 258 patients with PAVMs, no patient reported platypnea [<a href="#rid24">24</a>]. In contrast, several studies have found orthodeoxia (ie, a decrease in the oxyhemoglobin saturation by 2 percent or more when rising from the supine to the upright position) was reported in at least 30 percent of patients [<a href="#rid24">24-27</a>]. Platypnea and orthodeoxia are not unique to PAVM; they may also occur with the hepatopulmonary syndrome, atrial septal defects (including patent foramen ovale), and other conditions [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H111281894"><span class="h3">Chest pain and cough</span><span class="headingEndMark"> — </span>Other less common symptoms that may be seen among patients with PAVM include chest pain and cough, presumably related to pleural or endobronchial involvement [<a href="#rid13">13,18</a>].</p><p class="headingAnchor" id="H111281916"><span class="h3">Clubbing and cyanosis</span><span class="headingEndMark"> — </span>Clubbing and cyanosis indicate severe and/or multiple/diffuse PAVMs  (<a class="graphic graphic_table graphicRef79966" href="/z/d/graphic/79966.html" rel="external">table 1</a>). In older case series, they were often seen in more than half of patients [<a href="#rid2">2,14,15,29</a>], but they have been observed less often (&lt;5 percent) in subsequent series [<a href="#rid13">13,18</a>].</p><p class="headingAnchor" id="H111281924"><span class="h3">Murmurs and bruits</span><span class="headingEndMark"> — </span>Murmurs or bruits auscultated over the PAVMs are auscultated in less than 10 percent of cases of PAVMs  (<a class="graphic graphic_table graphicRef79966" href="/z/d/graphic/79966.html" rel="external">table 1</a>). The murmurs are loudest during inspiration and more likely to be heard when the PAVM is in a dependent position. (See  <a class="medical medical_review" href="/z/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults", section on 'Arteriovenous fistulas'</a>.)</p><p class="headingAnchor" id="H259348341"><span class="h2">Features attributable to HHT</span><span class="headingEndMark"> — </span>The most common clinical manifestations of hereditary hemorrhagic telangiectasia (HHT) are epistaxis, mucocutaneous telangiectases  (<a class="graphic graphic_picture graphicRef52483" href="/z/d/graphic/52483.html" rel="external">picture 1</a>), gastrointestinal (GI) bleeding from GI tract telangiectases, and blood loss anemia  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 2</a>). About one-third of patients with HHT have dyspnea, although the proportion of this group that have PAVMs is unclear [<a href="#rid21">21</a>]. Detailed discussion of the clinical manifestations of HHT is provided separately. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Clinical features'</a>.)</p><p>Telangiectases on the skin and mucous membranes are usually flat or slightly papular, ruby colored, 1 to 3 mm in diameter, and sharply demarcated from the surrounding skin. In addition, they tend to blanch easily with pressure and are most commonly located on the face, tongue, lips, and distal upper extremities  (<a class="graphic graphic_picture graphicRef77416" href="/z/d/graphic/77416.html" rel="external">picture 2</a>) [<a href="#rid12">12</a>]. These characteristics differentiate telangiectases on the skin from the spider nevi that are common in advanced liver disease, which are almost always flat, blanch readily, refill centrally first, and are mainly found on the face and anterior chest. Capillary microscopy of the finger nail bed is a simple and noninvasive technique that may occasionally reveal abnormal capillary loops in patients without characteristic telangiectases, although this test is rarely performed. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Nailfold capillary microscopy'</a>.)</p><p>Importantly, some patients with HHT may present with PAVMs as their only manifestation or have limited findings of HHT [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H259348407"><span class="h2">Features attributable to PAVM complications</span><span class="headingEndMark"> — </span>PAVMs can be associated with a variety of complications, some of which are life-threatening, including stroke, brain abscess, and hemoptysis  (<a class="graphic graphic_table graphicRef77215" href="/z/d/graphic/77215.html" rel="external">table 4</a>). The true incidence of patients that <strong>initially</strong> present with a complication is unknown but probably about 15 to 30 percent in the era of CT evaluation of patients with HHT for PAVMs. The spectrum and rate of complications from retrospective case series, where screening was not commonly performed, are discussed in detail below.</p><p class="headingAnchor" id="H111280348"><span class="h3">Neurologic</span><span class="headingEndMark"> — </span>The rate of neurologic complications in patients with PAVMs ranges from 9 to 41 percent in several large series published since 2004 [<a href="#rid4">4-9</a>]. The most common neurologic complications are stroke and brain abscess, but patients can also suffer from seizures, migraines, hemorrhage, headaches, dizziness, syncope, diplopia, and tinnitus [<a href="#rid13">13,18</a>]. Higher rates of stroke or brain abscess have been reported in those with diffuse PAVMs (up to 70 percent) [<a href="#rid3">3,29,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a>.)</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>One series of 76 consecutive patients undergoing embolotherapy reported the following frequency of neurologic events [<a href="#rid25">25</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CT evidence of stroke – 36 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic stroke – 18 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Transient ischemic attack – 37 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Brain abscess – 9 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Migraine headache – 43 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Seizure – 8 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Cerebral arteriovenous malformation (CAVM) – 5 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A case series of 219 patients with PAVM found evidence for neurologic events in 34 percent including clinical stroke in 14 percent and brain abscess in 13 percent [<a href="#rid7">7</a>].</p><p></p><p>Paradoxical embolization across a PAVM is the most likely mechanism for both strokes and brain abscesses, which is also supported by the observation that these complications are more frequent in patients with feeding arteries &gt;2 to 3 mm in diameter. The mechanism for seizures, migraines, and other neurologic symptoms is less clear, but cerebral hypoxia due to shunting through PAVMs or symptoms due to concurrent CAVMs may contribute. Cerebral hemorrhage may be a complication of embolic stroke or due to a ruptured CAVM.</p><p>The risk of neurologic complications increases with the number of PAVMs and the patient’s age [<a href="#rid31">31,32</a>]. As an example, in one case series of 75 patients with PAVMs, radiologic evidence of cerebral infarction was found in 32 percent of patients with single PAVMs and 60 percent of patients with multiple PAVMs [<a href="#rid31">31</a>]. In another study of 71 patients with HHT and PAVM, embolic neurologic complications (ie, stroke, transient ischemic attack, or cerebral abscess) occurred in 10 percent of patients less than 30 years old and 45 percent of older patients [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H111280621"><span class="h3">Hemothorax and hemoptysis</span><span class="headingEndMark"> — </span>Hemoptysis of any significant degree (more than blood streaking) in a patient with known PAVMs should be considered a medical emergency, prompting urgent hospitalization, evaluation, and institution of appropriate treatment. Hemothorax and hemoptysis occur in less than 10 to 20 percent of patients with PAVMs, but are potentially life-threatening [<a href="#rid4">4,8,9,33</a>]. Hemothorax results from rupture of a subpleural PAVM, while hemoptysis is likely due to rupture of either a parenchymal PAVM or an endobronchial telangiectasia. In a series of 143 patients with PAVMs who were referred for embolotherapy, 11 patients (8 percent) had a history of hemoptysis or hemothorax requiring hospitalization [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a>.)</p><p>Pulmonary hemorrhage may occur during pregnancy, especially during the third trimester and can be fatal. Pregnancy may exacerbate PAVMs through increased blood volume, increased cardiac output, and increased vascular distensibility, all of which promote increased blood flow through PAVMs. As a result, women with HHT should be evaluated for PAVMs and treated maximally <strong>before</strong> pregnancy, although treatment may be safely undertaken during pregnancy (preferably between 16 and 26 weeks of gestation), if required [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a> and  <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H111280734"><span class="h3">Polycythemia and anemia</span><span class="headingEndMark"> — </span>Polycythemia and anemia were each seen in approximately 18 percent of patients with PAVMs in older series but polycythemia is now rare [<a href="#rid13">13,14,17,36</a>]. Polycythemia is likely due to chronic hypoxemia, and anemia is due to blood loss from epistaxis and/or associated gastrointestinal lesions related to underlying HHT. (See  <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a> and  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p class="headingAnchor" id="H111280802"><span class="h3">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Approximately 10 percent of patients with PAVMs associated with HHT have pulmonary hypertension [<a href="#rid3">3,29,37-39</a>]. As an example, one study of 143 patients undergoing PAVM embolization reported that 9 percent of patients had a mean pulmonary artery pressure &gt;20 mmHg and 6 percent had a pressure &gt;25 mmHg [<a href="#rid37">37</a>]. Another study of 651 HHT patients undergoing PAVM embolization reported that 13 percent of patients had a mean pulmonary artery pressure ≥25 mmHg and 2.8 percent had a pressure &gt;35 mmHg [<a href="#rid39">39</a>]. Importantly, the elevated pulmonary vascular pressures and flow may predispose to enlargement of the underlying PAVM, leading to an increased risk of rupture [<a href="#rid38">38</a>] and possibly mortality [<a href="#rid39">39</a>].</p><p>The development of pulmonary hypertension is not directly due to the PAVM itself, but rather due to one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent hepatic disease where chronic left-to-right shunting through hepatic AVMs causes high output left heart failure (ie, group 2 pulmonary hypertension) or portopulmonary hypertension (ie, group 1 pulmonary artery hypertension) [<a href="#rid3">3,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/3462.html" rel="external">"Causes and pathophysiology of high-output heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/8266.html" rel="external">"Portopulmonary hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Postdiagnostic testing and classification'</a>.)</p><p></p><p class="bulletIndent1">Pulmonary artery catheterization will distinguish group 1 from group 2 pulmonary hypertension. Patients with high output left heart failure (group 2) typically have an elevated pulmonary artery wedge pressure (PAWP), a markedly increased cardiac index (CI), and a normal pulmonary vascular resistance, while those with portopulmonary hypertension (group 1) have normal PAWP, a normal or low cardiac index, and a high pulmonary vascular resistance. In one study, 73 percent of patients with measurement of cardiac output were diagnosed as having postcapillary pulmonary hypertension [<a href="#rid39">39</a>], highlighting the importance of catheterization for an accurate diagnosis. (See  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heritable pulmonary arterial hypertension (PAH) in patients with concomitant HHT, which is indistinguishable clinically from idiopathic pulmonary arterial hypertension (IPAH) and is usually related to defects in ALK-1 (ie, product of the HHT 2 gene) [<a href="#rid40">40-42</a>]. One study identified ten patients with pulmonary hypertension from four families with HHT, four of whom had histology-proven IPAH [<a href="#rid41">41</a>]. Genetic linkage analysis in those patients was consistent with alterations in ALK-1, which has a documented role in the pathogenesis of IPAH [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New or increased pulmonary hypertension may occur following embolization or resection of large or multiple PAVMs, especially when the pretreatment shunt fraction is greater than 20 percent [<a href="#rid43">43,44</a>]. When PAVMs are obliterated during embolotherapy or resected, flow is redirected through residual pulmonary vasculature. A relative increase in flow through the residual pulmonary vascular bed may increase pulmonary vascular pressure, particularly in those with mild or subclinical pulmonary hypertension at baseline. The value of pulmonary artery catheterization in predicting post embolization pulmonary pressures is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Procedural complications'</a>.)</p><p></p><p class="headingAnchor" id="H111281131"><span class="h3">Other complications</span><span class="headingEndMark"> — </span>Other complications of PAVM include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non neurologic systemic embolization</strong> – There are anecdotal reports of patients with infectious endocarditis, and abscesses in the soft tissue, muscle, or other organs (eg, spleen), all presumably due to paradoxic embolization [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications of HHT</strong> – Patients with underlying HHT can suffer from epistaxis, gastrointestinal hemorrhage, and skin bleeding  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 2</a>) [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth</strong> – Most PAVMs remain stable in size. However, approximately 25 percent of PAVMs will enlarge <strong>slowly</strong>, usually at a rate of 0.3 to 2 mm/year [<a href="#rid11">11,14</a>]. Macroscopic PAVMs do not spontaneously resolve. (See  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Natural history'</a>.)</p><p></p><p class="headingAnchor" id="H259348425"><span class="h2">Imaging findings</span><span class="headingEndMark"> — </span>Conventional chest radiography  (<a class="graphic graphic_diagnosticimage graphicRef57484" href="/z/d/graphic/57484.html" rel="external">image 3</a>) and/or nonenhanced CT of the chest  (<a class="graphic graphic_diagnosticimage graphicRef102809" href="/z/d/graphic/102809.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef102810" href="/z/d/graphic/102810.html" rel="external">image 5</a> and <a class="graphic graphic_diagnosticimage graphicRef127977" href="/z/d/graphic/127977.html" rel="external">image 6</a>) are abnormal in most patients who have symptoms attributable to PAVMs [<a href="#rid2">2,11,13,14,16,17,36,46-49</a>]. While the typical appearances of PAVMs on chest radiography and CT are similar (ie, a smooth nodule with a feeding artery and draining vein), in the era of CT evaluation of HHT patients and frequent use of CT in the general population, many patients present with atypical findings on chest CT [<a href="#rid50">50</a>]. Pulmonary angiography is not routinely used for the diagnostic evaluation of suspected PAVMs except in the setting of concomitant embolotherapy. In most centers in the United States, magnetic resonance imaging (MRI) is rarely used for the routine evaluation of suspected PAVM. A concise review of the appropriateness of various modalities for imaging PAVM has been published by the American College of Radiology [<a href="#rid51">51</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiography</strong> – Typical chest radiographic findings include a smooth nodule(s) with linear parallel shadows representative of the feeding pulmonary artery and draining pulmonary vein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Computed tomography</strong> – In a study of 108 patients with definite HHT and PAVM who also had CT scans, 62 percent had multiple lesions and 11 percent had 10 or more lesions [<a href="#rid4">4</a>]. <strong>Typical</strong> CT imaging characteristics that together are considered diagnostic include the following  (<a class="graphic graphic_diagnosticimage graphicRef99565" href="/z/d/graphic/99565.html" rel="external">image 7</a> and <a class="graphic graphic_diagnosticimage graphicRef102808" href="/z/d/graphic/102808.html" rel="external">image 8</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Round or oval nodule (&lt;3 cm) or mass (≥3 cm) of uniform density (ie, the "sac").</p><p class="bulletIndent2"><span class="glyph">•</span>Well demarcated smooth borders with occasional lobulation.</p><p class="bulletIndent2"><span class="glyph">•</span>Usually 0.5 to 5 cm in diameter, but occasionally exceeding 10 cm in diameter.</p><p class="bulletIndent2"><span class="glyph">•</span>Usually 2 to 8 lesions among the patients who have multiple PAVMs [<a href="#rid4">4</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>Visible feeding vessels that are visualized on CT as tubular structures, often parallel, that seamlessly blend into/terminate at the sac; the artery radiates from the hilum and the vein deviates toward the left atrium. Vessels are also typically larger than other vessels in the vicinity (especially for peripheral lesions).</p><p class="bulletIndent2"><span class="glyph">•</span>Good contrast enhancement on CT if the sac is 1 cm or greater and if contrast is used. Contrast is not necessary for diagnosis.</p><p></p><p class="bulletIndent1">Importantly, not all patients present with these classic findings. <strong>Atypical</strong> findings on CT include an irregular sac with poorly defined borders, only one tubular structure leading into the sac, a tubular structure that continues past the nodule/sac, and irregular or no contrast enhancement  (<a class="graphic graphic_diagnosticimage graphicRef102806" href="/z/d/graphic/102806.html" rel="external">image 9</a>). In some cases, these findings may indicate other diagnoses such as tumors or other vascular malformations such as systemic artery to pulmonary artery malformations or pulmonary vein varices [<a href="#rid50">50</a>]. (See <a class="local">'Computed tomography'</a> below.)</p><p></p><p class="bulletIndent1">Telangiectatic-type PAVMs are another atypical finding in which an area of ground-glass density, typically 0.5 to 3 cm, is seen on CT  (<a class="graphic graphic_diagnosticimage graphicRef135043" href="/z/d/graphic/135043.html" rel="external">image 10</a>). These are often associated with small- to moderate-sized feeding and draining vessels and may be associated with a smaller central tangle of vessels that have not yet coalesced into a typical "sac." Investigations are ongoing to determine the risk profile of these telangiectatic-type PAVMs and whether they turn into typical PAVMs over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conventional pulmonary angiography</strong> – Pulmonary arterial angiography is the gold standard for defining the anatomy of PAVMs identified previously on CT that are considered potentially suitable for embolotherapy but is also occasionally performed for the sole purposes of definitive diagnosis  (<a class="graphic graphic_diagnosticimage graphicRef102812" href="/z/d/graphic/102812.html" rel="external">image 11</a> and <a class="graphic graphic_diagnosticimage graphicRef54651" href="/z/d/graphic/54651.html" rel="external">image 12</a> and <a class="graphic graphic_diagnosticimage graphicRef102813" href="/z/d/graphic/102813.html" rel="external">image 13</a> and <a class="graphic graphic_diagnosticimage graphicRef100433" href="/z/d/graphic/100433.html" rel="external">image 14</a>) [<a href="#rid47">47</a>]. Typical findings include the demonstration of a feeding artery leading to the abnormal arteriovenous communication, which is drained by a pulmonary vein  (<a class="graphic graphic_diagnosticimage graphicRef100434" href="/z/d/graphic/100434.html" rel="external">image 15</a>). (See <a class="local">'Pulmonary angiography'</a> below and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Magnetic resonance angiography</strong> – Although MRI may show similar findings to those seen on CT, it is not as sensitive or as specific diagnostically. It is also more expensive, and highly specialized expertise is required for accurate interpretation. (See <a class="local">'Magnetic resonance imaging'</a> below.)</p><p></p><p class="headingAnchor" id="H259348893"><span class="h2">Laboratory tests</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General</strong> – Patients with PAVMs may have anemia or polycythemia when they occur in association with HHT involvement of the nasal passages and gastrointestinal tract or with long standing hypoxemia, respectively. (See  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a> and  <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a> and  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arterial blood gases</strong> – The incidence of hypoxemia in PAVM is highly variable and depends on how patients were accrued. In one series in which PAVM were diagnosed by screening HHT patients, 80 percent of patients had a SaO<sub>2</sub> of 96 percent or higher. (See  <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia"</a>.)</p><p></p><p class="bulletIndent1">Patients with diffuse PAVMs are uniformly hypoxemic  (<a class="graphic graphic_diagnosticimage graphicRef102814" href="/z/d/graphic/102814.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef102815" href="/z/d/graphic/102815.html" rel="external">image 2</a>), with a mean arterial oxygen tension (PaO<sub>2</sub>) of 47 mmHg according to a series of 16 patients with PAVMs [<a href="#rid29">29</a>]. Other case series have found that 81 to 100 percent of patients with PAVMs have either a PaO<sub>2</sub> &lt;80 mmHg or an SaO<sub>2</sub> &lt;97 to 98 percent on room air [<a href="#rid14">14,16,17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orthodeoxia</strong> – Orthodeoxia is the laboratory correlate of platypnea. It is defined as a decrease in the oxyhemoglobin saturation by 2 percent or more when rising from the supine to the upright position, the details of which are discussed above. (See <a class="local">'Platypnea and orthodeoxia'</a> above.)</p><p></p><p class="headingAnchor" id="H259354691"><span class="h2">Cardiopulmonary exercise testing</span><span class="headingEndMark"> — </span>Cardiopulmonary exercise testing is usually performed in patients with unexplained dyspnea and is not typically performed in patients with PAVM for diagnosis. Most patients with PAVM have reduced exercise tolerance; however, their exercise tolerance tends to be better maintained than patients who have an equivalent degree of hypoxemia from another cause [<a href="#rid52">52-54</a>]. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea", section on 'Cardiopulmonary exercise testing'</a> and  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea", section on 'Cardiopulmonary exercise testing with pulmonary artery catheterization'</a>.)</p><p>As an example, a study of 15 patients with PAVM reported that 73 percent achieved &gt;70 percent of their predicted maximum workload despite their SaO<sub>2</sub> decreasing from 86 percent at rest to 73 percent with peak exercise [<a href="#rid53">53</a>]. Patients with similar degrees of hypoxemia due to other cardiac and pulmonary diseases have considerably less tolerance for exercise due to an increase in baseline pulmonary vascular resistance that prevents an appropriate increase in cardiac output during exercise. Presumably, patients with PAVM are able to increase pulmonary blood flow appropriately during exercise due to a subnormal pulmonary vascular resistance [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H259351609"><span class="h1">INDICATIONS FOR DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>PAVMs should be suspected and a diagnostic evaluation initiated in individuals with one or more of the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical features suggestive of PAVMs  (<a class="graphic graphic_table graphicRef79966" href="/z/d/graphic/79966.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary nodule(s) on chest imaging that is suspicious for PAVM. (See <a class="local">'Imaging findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stigmata of right-to-left shunting, such as dyspnea, hypoxemia, polycythemia, clubbing, cyanosis, cerebral embolism, or a brain abscess.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unexplained hemoptysis, hemothorax, hypoxemia, or dyspnea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Platypnea or orthodeoxia.</p><p></p><p class="bulletIndent1">The clinical features of PAVMs are discussed in detail separately. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected or known diagnosis of hereditary hemorrhagic telangiectasia (HHT; Osler Weber Rendu syndrome). As examples, those with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mucocutaneous telangiectases or other features suggestive of HHT  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Personal history of HHT (including pregnant women).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history of HHT.</p><p></p><p class="bulletIndent1">Individuals with a personal or family history of HHT should be evaluated for possible PAVMs, since there is a high incidence of unsuspected PAVMs in this population [<a href="#rid10">10,11,55-57</a>]. This is particularly important if at least one member of the family with HHT has already been diagnosed with PAVM, as the incidence of PAVM is approximately 35 percent among relatives [<a href="#rid57">57,58</a>]. It is also recommended that all women with HHT undergo evaluation before becoming pregnant, since PAVMs are associated with a high incidence of hemoptysis or hemothorax during the last half of pregnancy [<a href="#rid34">34</a>]. Issues regarding evaluating patients with HHT for undetected PAVMs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a> and  <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">"Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults", section on 'Hereditary hemorrhagic telangiectasia (HHT)'</a> and  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Overview of screening strategy'</a>.)</p><p></p><p>PAVMs are more common with HHT-1 than HHT-2 mutations but both populations are at risk and should be screened. Genetic evaluation of patients with HHT and evaluation for cerebral AVMs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)", section on 'Cerebral vascular abnormalities'</a> and  <a class="medical medical_review" href="/z/d/html/123017.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Routine care including screening for asymptomatic AVMs", section on 'Genetic counseling and testing of family members'</a>.)</p><p class="headingAnchor" id="H199140695"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>For patients with suspected PAVMs, we and others agree that transthoracic contrast echocardiography (TTCE) is the initial test of choice to evaluate for the presence of a right-to-left shunt [<a href="#rid59">59</a>]. Subsequent diagnostic testing with nonenhanced CT of the chest depends upon the identification and severity (ie, grade) of shunt found on TTCE. Our preferred approach is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef102804" href="/z/d/graphic/102804.html" rel="external">algorithm 1</a>) and the sections below.</p><p class="headingAnchor" id="H259352182"><span class="h2">Shunt fraction assessment</span><span class="headingEndMark"> — </span>PAVMs, particularly large and multiple PAVMs, shunt blood directly from the pulmonary artery to the pulmonary vein such that shunted blood is poorly oxygenated. TTCE is the test of first choice for the evaluation of a right-to-left shunt due to suspected PAVMs. Importantly, TTCE is not diagnostic of PAVMs but does indicate the presence of a shunt. The 100 percent oxygen method and radionuclide perfusion scanning can be used as alternatives for the measurement of shunt when TTCE is not helpful, equivocal, or not available. Among these options, TTCE is the only test that can differentiate shunt at the level of the lung from heart and great vessels, thereby making it more useful for the diagnostic evaluation of pulmonary (and cardiac) AVMs.</p><p class="headingAnchor" id="H259352188"><span class="h3">Transthoracic contrast echocardiography</span><span class="headingEndMark"> — </span>TTCE (also known as "bubble echocardiography") is the preferred initial test for patients who have an indication for diagnostic evaluation [<a href="#rid56">56,57,59-65</a>]. For most patients with suspected PAVMs in whom diagnostic testing is indicated, based upon its high sensitivity and low risk, TTCE is the initial test of choice to evaluate for the presence of a PAVM-associated right-to-left shunt. Subsequent diagnostic testing with nonenhanced CT of the chest depends upon the identification and severity (ie, grade) of shunt found on TTCE  (<a class="graphic graphic_algorithm graphicRef102804" href="/z/d/graphic/102804.html" rel="external">algorithm 1</a>). (See <a class="local">'Indications for diagnostic evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/5301.html" rel="external">"Contrast echocardiography: Contrast agents, safety, and imaging technique"</a> and  <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">"Contrast echocardiography: Clinical applications"</a>.)</p><p>TTCE is highly sensitive for the diagnosis of shunt from PAVMs [<a href="#rid56">56,57,60,62-64</a>]. TTCE identifies PAVM-associated shunt with a sensitivity, specificity, positive predictive value, and negative predictive value of 100, 49, 32, and 100 percent, respectively [<a href="#rid63">63</a>]. One cited potential limitation of TTCE is that it may be too sensitive, detecting clinically unimportant PAVMs [<a href="#rid66">66-68</a>]. This was illustrated by several studies that found that TTCE continued to detect intrapulmonary shunting in 80 percent of patients even after successful embolization of all visible PAVMs [<a href="#rid68">68</a>].</p><p>TTCE involves the injection of echocardiographic contrast, usually 10 to 20 mL of agitated <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (generates microbubbles), into a peripheral vein while simultaneously imaging the right and left ventricles with two-dimensional echocardiography. The contrast is normally visualized in the right ventricle soon after injection and should not be visualized in the left cardiac chambers at all (microbubbles are filtered out by the pulmonary capillary network). The appearance of contrast in the left ventricle (microbubbles) is consistent with right-to-left shunt. The Valsalva maneuver is not necessary and is not recommended when screening for PAVM as shunting from PAVMs is continuous and the Valsalva maneuver may artificially open a patent foramen ovale or other shunt, yielding a false positive result.</p><p>PAVMs are not directly visualized on echocardiography but shunts of cardiac or great vessel origin may be directly visualized which may help to distinguish PAVMs from other anatomic shunts. Visualizing an intracardiac shunt by TTCE should not preclude further evaluation of possible PAVMs if the suspicion for PAVMs is high. For example, in the presence of an atrial right-to-left shunt, contrast will appear in the left atrium immediately and therefore obscure any delayed shunt from a PAVM. In this case, TTCE or especially transesophageal echocardiogram (TEE) may be used to diagnose PAVM by looking for contrast in the pulmonary veins [<a href="#rid69">69</a>].</p><p>In the case of right–to-left shunt, contrast first appears in the right ventricle and then the left ventricle. The number of cardiac cycles that elapse between first appearance of contrast in the right ventricle and left ventricle can help to anatomically locate the shunt and, if visualized, microbubbles are counted so that the degree of shunting can be graded:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – When microbubbles are seen in the left ventricle in less than one cardiac cycle of their appearance in the right ventricle, this is typically associated with an intracardiac shunt; in greater than three but less than eight cycles is consistent with an intrapulmonary shunt; and between one to three cardiac cycles the location of the shunt is indeterminate (ie, the shunt could be located within the heart, great vessels, or lung) [<a href="#rid60">60,61,65,70,71</a>]. However, the location of shunt using this method has not been validated and is considered by many experts as a general guideline only because timing of contrast depends upon many factors including cardiac output, shunt size, and heart rate. For example, the shunt from large PAVM may occasionally be seen within one cardiac cycle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Grading</strong> – Many experts grade the degree of shunting seen on TTCE in order to select those suitable for diagnostic CT scanning [<a href="#rid57">57,62,63,72-74</a>]. Although there is little evidence to support the use of one grading system over another, we and some other experts prefer to use a quantitative grading system due to a preponderance of evidence to support its use [<a href="#rid57">57,65</a>]. Subsequent diagnostic testing with nonenhanced CT of the chest varies depending upon the grade:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 0</strong> – Grade 0 refers to no bubbles reaching the left ventricle (ie, no right-to-left shunt). In general, patients whose TTCE finds no shunt require no further evaluation for PAVM unless there is a high clinical suspicion for PAVM, such as unexplained hypoxemia, suspicious nodule on imaging, or evidence to suggest paradoxical embolization (eg, stroke). In such patients, additional testing may include measurement of the shunt fraction by the 100 percent oxygen method, radionuclide perfusion scanning, or chest CT; chest CT is our preference. The preference for CT is based upon the higher diagnostic sensitivity compared with 100 percent oxygen and radionuclide perfusion scanning. For patients with no shunt and low clinical suspicion for PAVM (eg, a nodule with some features suggestive of cancer), additional investigations for the presenting complaint are indicated. In patients with hereditary hemorrhagic telangiectasia (HHT) and a grade 0 shunt, some experts will repeat TTCE in 5 to 10 years to follow for development of new PAVM, though this is clinical practice that is unproven. One study performed repeat TTCE five years later in 86 patients with HHT and grade 0 shunt and found that 26 percent developed a grade 1 shunt, though no one developed treatable PAVM or increased to grade 2 shunt during that time [<a href="#rid75">75</a>]. In another study of 172 HHT patients with initially negative TTCE or CT scan, 5.2 percent developed new PAVM over a median of seven years, including one with a feeding artery diameter (FAD) of 3 mm [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 1</strong> – Grade 1 refers to 1 to 29 bubbles seen in the left ventricle on the still frame with the largest number of bubbles. Although historically many of these patients were subjected to further diagnostic testing, in practice most patients with a grade 1 shunt do not require further investigation for PAVM. This is because there appears to be no difference in the risk of paradoxical embolization or bleeding between the two groups (1.8 percent risk with grade 0 shunt, 0.4 percent risk with grade 1 shunt) and while a PAVM is occasionally discovered with CT following a grade 1 TTCE, such PAVMs are almost always too small to require embolization [<a href="#rid33">33,74</a>].</p><p></p><p class="bulletIndent2">We generally advise the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In most patients with grade 1 shunt, no further evaluation is performed and patients should undergo yearly observation clinically for the development of progressive symptoms which may prompt a repeat TTCE. Many experts consider it prudent in this population that a repeat TTCE be performed within five years so that small PAVMs that may have grown during that interval will be detected. Shorter intervals (weeks or months) are not required due to the slow growth of PAVMs. One study performed repeat TTCE five years later in 55 patients with HHT and grade 1 shunt and found that 17 percent developed a grade 2 shunt, and some of these developed treatable PAVM [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with a grade 1 shunt where the clinician has a high suspicion for clinically significant PAVM including unexplained hypoxemia, suspicious nodule on imaging, or evidence to suggest paradoxical embolization (eg, stroke), we prefer diagnostic testing with chest CT to confidently diagnose or exclude treatable PAVM. (See <a class="local">'Computed tomography'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Grade 2 or 3</strong> – Grade 2 shunt (30 to 100 bubbles in the left ventricle) or grade 3 shunt (&gt;100 bubbles in the left ventricle) should undergo chest CT scanning next. (See <a class="local">'Computed tomography'</a> below.)</p><p></p><p class="bulletIndent1">This approach is based upon our clinical experience and observational studies that report low likelihood of a treatable PAVM (&lt;2 percent) in patients with grade 1 shunt [<a href="#rid33">33,63</a>] and that higher grade shunt is more likely to be associated with the detection of symptomatic PAVMs that require therapy [<a href="#rid33">33,63,72,74</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TTCE and thoracic CT were performed in 95 patients with HHT using a 4 point grading system (as opposed to the 3 point system described above). No patient with grade 0 or grade 1 shunt on TTCE was found to have PAVMs by thoracic CT [<a href="#rid73">73</a>]. In contrast, 25, 80, and 100 percent of patients with grade 2, 3, and 4 shunts, respectively, were found to have PAVM by CT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the results from four studies that used a grading scale were pooled, none of the 178 patients with a grade 1 shunt had treatable PAVMs on CT scan and only 6 percent had any visible PAVMs on CT [<a href="#rid57">57,62,63,73</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another study of 1038 patients with HHT, pulmonary shunt grade 2 and 3 were both independent predictors for the prevalence of a cerebral ischemic event or brain abscess (odds ratio [OR] 4.78, 95% CI 1.14-20 and OR 10.4, 95% CI 2.4-45, respectively) [<a href="#rid33">33</a>]. In addition, patients with a grade 1 shunt were no more likely to suffer cerebral complications than those with a grade 0 shunt (OR 0.44) [<a href="#rid33">33</a>].</p><p></p><p>The optimal test for patients with an <strong>indeterminate</strong> TTCE (eg, appearance of contrast in the left atrium within 1 to 3 cardiac cycles or poor visualization of contrast or chambers due to poor technique) is unknown. We believe that the presence of shunt on TTCE in HHT patients should be assumed to be due to PAVM rather than an intracardiac shunt, even if seen before three cycles. If workup for PAVM is negative, then intracardiac shunts should be looked for with transesophageal echocardiography. In the case of poor visualization, we suggest that the clinical suspicion direct the course of investigation: observation may be appropriate in those with a low suspicion for PAVM; a repeat TTCE for those with poor technical views; or a CT chest for those with a high suspicion for PAVM.</p><p>The techniques, safety, and clinical applications of contrast echocardiography are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5301.html" rel="external">"Contrast echocardiography: Contrast agents, safety, and imaging technique"</a> and  <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">"Contrast echocardiography: Clinical applications"</a>.)</p><p class="headingAnchor" id="H259352647"><span class="h3">Other</span><span class="headingEndMark"> — </span>Several additional methods exist to measure shunt. These include measuring arterial oxygen and carbon dioxide tension on 100 percent oxygen, oxygen saturation on room air, alveolar-arterial gradient, and radionuclide perfusion scanning. In general, these methods can be used to confirm the suspicion of shunt when TTCE is not available or is equivocal, but they are not as well validated as TTCE.</p><p class="headingAnchor" id="H259352343"><span class="h4">100 percent oxygen</span><span class="headingEndMark"> — </span>The shunt fraction is the fraction of the cardiac output that bypasses the pulmonary capillaries. It can be determined by the 100 percent oxygen method, which involves measuring the arterial oxygen tension (PaO<sub>2</sub>) and saturation (SaO<sub>2</sub>) and the arterial carbon dioxide tension (PaCO<sub>2</sub>) after breathing 100 percent oxygen through a mouthpiece or airtight mask for 15 to 20 minutes and then using those values to calculate the shunt fraction [<a href="#rid3">3</a>]. A shunt fraction of &gt;5 percent is considered abnormal and warrants additional evaluation. (See  <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia"</a>.)</p><p>The sensitivity of the shunt fraction at detecting PAVMs depends upon whether the PAVMs are clinically significant or asymptomatic. A shunt fraction &gt;5 percent appears to detect approximately 98 percent of clinically significant PAVMs [<a href="#rid3">3,13,16,67,77</a>], but only 88 percent of asymptomatic PAVMs [<a href="#rid55">55</a>]. The magnitude of the shunt fraction varies among patients with PAVMs, with values ranging from 14 to 55 percent [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H259358544"><span class="h4">Oxygen saturation on room air</span><span class="headingEndMark"> — </span>When the shunt fraction cannot be measured using the 100 percent oxygen method, an alternative approach is to measure the PaO<sub>2</sub> and arterial oxyhemoglobin saturation (SaO<sub>2</sub>) while the patient is breathing room air. A PaO<sub>2</sub> &gt;95 mmHg and an SaO<sub>2</sub> &gt;96.5 percent effectively excludes a significant shunt, while a PaO<sub>2</sub> &lt;85 mmHg or an SaO<sub>2</sub> &lt;96 percent suggests a shunt fraction &gt;5 percent [<a href="#rid3">3,77</a>]. However, this method is less specific than the 100 percent oxygen method because it does not differentiate a true shunt (either anatomic or physiologic) from ventilation-perfusion mismatch. The use of pulse oximetry alone is an insensitive screening method for PAVM and should not be used for this purpose, except perhaps in children where arterial puncture is generally avoided [<a href="#rid78">78</a>]. In the case of screening children for PAVM, we measure pulse oximetry in the supine position and then every 15 seconds for 2 minutes after assuming the seated position; a saturation of &lt;96 percent in either position is considered abnormal.</p><p class="headingAnchor" id="H259358550"><span class="h4">Alveolar-arterial oxygen tension gradient</span><span class="headingEndMark"> — </span>The alveolar-arterial PaO<sub>2</sub> gradient is not routinely used to measure shunt. However, some clinicians have used it instead of the shunt fraction to identify PAVMs. One study of 105 patients with hereditary HHT who were being evaluated for treatable PAVMs found that an alveolar-arterial gradient &gt;24.5 kPa (184 torr) measured while breathing 100 percent oxygen in the upright position detected PAVMs with a sensitivity of only 59 percent [<a href="#rid56">56</a>]. This threshold was chosen because it corresponded with a shunt fraction &gt;5 percent in the investigators’ laboratory. However, the threshold corresponds to a shunt fraction of &gt;10 percent if conventional equations are used to determine the shunt fraction, which may explain why the sensitivity was so poor (ie, higher gradients are likely to cause a lower sensitivity and a higher specificity).</p><p class="headingAnchor" id="H259352293"><span class="h4">Radionuclide perfusion scanning</span><span class="headingEndMark"> — </span>Radionuclide perfusion lung scanning does not typically anatomically define a PAVM but can confirm or identify the presence of a right-to-left shunt. This test is useful if contrast-enhanced echocardiography or the 100 percent oxygen method for the evaluation of shunt is not available. The test involves the peripheral, intravenous injection of macroaggregated albumin labeled with technetium-99m (<sup>99m</sup>Tc). In healthy persons, these particles are filtered by pulmonary capillaries. However, in the presence of true right-to-left shunts, radiolabeled particles pass through the lungs (or intracardiac defects) and are trapped in the brain and kidneys. The shunt fraction may be calculated by quantifying the renal uptake as a percentage of the total dose given.</p><p>One study reported in 19 PAVM patients that the mean shunt fraction was 23 percent compared with 3 percent in normal subjects [<a href="#rid79">79</a>]. A second study of 66 patients with PAVM showed that a shunt of &gt;3.5 percent by the radionuclide method was 87 percent sensitive and 61 percent specific for detection of residual PAVM after embolotherapy [<a href="#rid80">80</a>].</p><p>The radionuclide method of shunt detection and calculation has several potential advantages over the 100 percent oxygen method:</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial blood sampling is not needed</p><p class="bulletIndent1"><span class="glyph">●</span>The 100 percent oxygen method may overestimate the shunt fraction if it is not performed correctly</p><p class="bulletIndent1"><span class="glyph">●</span>The radionuclide method allows shunt measurement during exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Radionuclide scanning can sometimes show the location of a PAVM [<a href="#rid3">3,79,81</a>]</p><p></p><p>However, radionuclide perfusion scanning can be expensive and is not routinely available at many hospitals. In addition, an abnormal radionuclide perfusion scan does not typically differentiate between intrapulmonary and intracardiac shunts.</p><p class="headingAnchor" id="H259354084"><span class="h2">Computed tomography</span><span class="headingEndMark"> — </span>CT is the test of choice for the diagnosis of PAVMs, particularly in patients with the following  (<a class="graphic graphic_algorithm graphicRef102804" href="/z/d/graphic/102804.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of grade 2 to 3 shunt by TTCE (or shunt &gt;5 percent by other modalities)</p><p class="bulletIndent1"><span class="glyph">●</span>A high suspicion for PAVMs together with a low grade (grade 1) shunt, equivocal evidence for shunt, or indeterminate shunt</p><p></p><p>Further testing is dependent upon the results of the CT scan:</p><p class="bulletIndent1"><span class="glyph">●</span>If the CT scan shows one or more PAVM with a <strong>FAD ≥2 to 3 mm diameter</strong>, the patient should be referred for pulmonary angiography and potential embolotherapy  (<a class="graphic graphic_diagnosticimage graphicRef102808" href="/z/d/graphic/102808.html" rel="external">image 8</a>). There is some controversy about the exact cutoff to use. In a survey study of HHT/PAVM experts, 80 percent used 2 mm as the cutoff, though some went even lower [<a href="#rid82">82</a>]. (See <a class="local">'Pulmonary angiography'</a> below and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a> and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Embolotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the CT scan shows PAVMs with a <strong>FAD &lt;2 mm</strong>, in most patients pulmonary angiography may be deferred unless patients have clinical features suggestive of symptomatic PAVM (eg, prior stroke with no other identifiable cause, hemoptysis, or significant hypoxemia). Notably, the presence of a cerebral abscess does not imply that a PAVM is treatable because an abscess can occur in a PAVM with a FAD of any size.</p><p></p><p class="bulletIndent1">For those in whom angiography is not performed, patients should undergo yearly observation clinically for the development of progressive symptoms, which may prompt a repeat TTCE and CT. Repeat CT can be performed after an appropriate interval to detect PAVMs that may grow to a size that is amenable to embolotherapy. Although this interval was historically recommended to be three to five years, longer intervals may be considered due to the slow growth of small PAVMs. A study of 88 patients with untreated PAVMs with a FAD &lt;2 mm who underwent long-term CT monitoring showed no statistically significant change in dimension over mean duration of 8.4 years [<a href="#rid83">83</a>]. In another study, PAVM enlargement was seen in 2 of 18 patients with small PAVMs but only after long follow-up times (7.9 and 10.7 years) and only one patient required treatment [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the CT scan is <strong>negative</strong> for PAVM and shunt is present on TTCE, microscopic PAVMs may be responsible for the shunt and follow-up as described above is prudent (ie, yearly clinical evaluation and at appropriate intervals if symptomatic). The established recommendation is to repeat assessment at three- to five-year intervals, but development of clinically significant PAVMs in this scenario is rare. One retrospective study of patients with microscopic PAVMs (positive TTCE but negative CT) found that only 2 of 48 patients developed visible PAVMs on CT after 6.8 years follow up, which were asymptomatic and too small to require embolization [<a href="#rid84">84</a>]. The optimal repeat imaging technique is unknown at this time [<a href="#rid82">82</a>]. At our center, if the degree of shunt on TTCE is grade 1, we usually revert back to contrast echocardiography and only repeat the CT scan if the severity of shunt worsens to grade 2 or 3. This approach is based on the low incidence of complications in patients with grade 1 shunt [<a href="#rid33">33</a>]. However, some centers continue to follow CT scans [<a href="#rid82">82</a>]. Pulmonary angiography is rarely performed in this population for patients with, for example, idiopathic stroke; however, in our experience, the likelihood of demonstrating a significant PAVM suitable for embolotherapy in this population is low.</p><p></p><p class="bulletIndent1">Alternatively, shunt may be due to hepatopulmonary syndrome (HPS) such that evaluation for HPS may be indicated. (See  <a class="medical medical_review" href="/z/d/html/8248.html" rel="external">"Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the CT scan is <strong>indeterminate</strong> (eg, atypical features suggestive but not diagnostic of PAVM  (<a class="graphic graphic_diagnosticimage graphicRef102806" href="/z/d/graphic/102806.html" rel="external">image 9</a>) (see <a class="local">'Imaging findings'</a> above)), further evaluation should be individualized. Some experts occasionally perform contrast pulmonary angiography in patients with high grade shunt and indeterminate CT scans in whom the clinical suspicion is high. However, observation with follow-up TTCE and/or CT is also appropriate (eg, those with minimal symptoms and/or a low grade shunt).</p><p></p><p>We prefer multidetector, thin cut (ie, 1 to 2 mm collimation) CT, which readily detects PAVMs; three-dimensional reconstruction facilitates delineation of the vascular structures  (<a class="graphic graphic_diagnosticimage graphicRef127977" href="/z/d/graphic/127977.html" rel="external">image 6</a>) [<a href="#rid85">85</a>]. Contrast material is not required, except for patients with atypical nodules on nonenhanced CT in whom the suspicion remains high (eg, large shunt, clinical symptoms of paradoxical embolization such as stroke). Diagnostic imaging findings on CT are discussed above. (See <a class="local">'Imaging findings'</a> above.)</p><p>This approach is based upon the high sensitivity of non-contrast-enhanced CT for the diagnosis of PAVMs. As an example, one study of 33 consecutive patients with 37 PAVMs compared non-contrast three-dimensional multidetector CT scanning with contrast-enhanced pulmonary angiography, which was the original gold standard at the time of the study [<a href="#rid49">49</a>]. CT provided reliable analysis of more PAVMs than unilateral pulmonary angiography (76 versus 32 percent), but fewer PAVMs than hyper-selective pulmonary angiography (76 versus 100 percent; ie, imaging the suspected PAVM only). (See <a class="local">'Pulmonary angiography'</a> below.)</p><p>CT is more sensitive than conventional chest radiography for detecting PAVMs. This is because on chest radiography, small PAVMs can be easily missed and discrete PAVMs are occasionally obscured by the diaphragms, heart shadow, or concomitant parenchymal lung disease. CT identifies nearly all PAVMs, even those that are poorly appreciated on conventional chest radiographs such that CT is the preferred imaging modality for diagnosis [<a href="#rid48">48,49</a>]. Thus, while a completely normal chest radiograph makes the diagnosis of symptomatic PAVM less likely, it should not preclude further evaluation with CT or angiography, particularly in a symptomatic patient with other features consistent with PAVM or HHT. As an example, in a symptomatic patient, CT of the chest may demonstrate multiple small PAVMs that are undetectable or present as a vague increase in pulmonary vascular markings on chest radiography [<a href="#rid14">14</a>].</p><p>Contrast-enhanced ultrafast (ie, electron beam) CT uses an electron beam rather than a conventional x-ray beam to obtain images. The electron beam obtains images more quickly and, therefore, motion artifact is minimized. In a study of 40 patients with suspected PAVM, contrast-enhanced ultrafast CT was more sensitive than selective pulmonary angiography at detecting PAVM (98 versus 60 percent), but selective pulmonary angiography was better at determining the angioarchitecture of individual PAVMs [<a href="#rid48">48</a>]. The disadvantage of contrast-enhanced electron beam CT compared with multidetector CT is that contrast is required, although they have not been compared with one another. (See  <a class="medical medical_review" href="/z/d/html/6982.html" rel="external">"Principles of computed tomography of the chest"</a>.)</p><p>The major advantages of CT scanning over pulmonary angiography are that it is noninvasive, is readily accessible, and does not require contrast material. Its disadvantages include the need for breath-holding and occasional mischaracterization of vascular tumors as PAVMs.</p><p>Low-dose radiation protocols are used by many centers with expertise for the evaluation of suspected PAVM.</p><p class="headingAnchor" id="H259354498"><span class="h2">Pulmonary angiography</span><span class="headingEndMark"> — </span>Catheter pulmonary angiography is the gold standard test for defining the vascular anatomy of PAVMs that are identified on prior CT as suitable for embolotherapy (ie, those with a feeding artery ≥2 to 3 mm in diameter)  (<a class="graphic graphic_diagnosticimage graphicRef102812" href="/z/d/graphic/102812.html" rel="external">image 11</a> and <a class="graphic graphic_diagnosticimage graphicRef102813" href="/z/d/graphic/102813.html" rel="external">image 13</a> and <a class="graphic graphic_diagnosticimage graphicRef100433" href="/z/d/graphic/100433.html" rel="external">image 14</a>). It will additionally detect the presence of unsuspected PAVMs in an individual patient, some of which may also be suitable for embolotherapy. Thus, it is generally performed with the primary purpose of diagnostic confirmation and therapeutic management (ie, embolotherapy) of PAVMs (see  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a>). Although it is not routinely performed in patients for purely diagnostic reasons (eg, small asymptomatic lesions found on CT), pulmonary angiography can be performed in those with symptomatic lesions where uncertainty persists after other tests (eg, atypical lesion on CT with high grade shunt of unidentified etiology)  (<a class="graphic graphic_algorithm graphicRef102804" href="/z/d/graphic/102804.html" rel="external">algorithm 1</a>). Diagnostic imaging findings on pulmonary angiography are discussed above. (See <a class="local">'Imaging findings'</a> above.)</p><p>During angiographic testing, contrast should be directly injected into the feeding artery or a distal pulmonary artery (ie, hyper-selective angiography) to accurately define the angioarchitecture of individual lesions  (<a class="graphic graphic_diagnosticimage graphicRef54651" href="/z/d/graphic/54651.html" rel="external">image 12</a>) [<a href="#rid48">48,49,86,87</a>]. Contrast should also be injected into the right and left main pulmonary arteries (ie, routine/unselective angiography) to detect additional PAVMs that may also be amenable to embolotherapy and to identify intra- or extra-thoracic vascular communications.</p><p class="headingAnchor" id="H199140985"><span class="h2">Other diagnostic tests</span></p><p class="headingAnchor" id="H259354163"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance (MR) angiography is rarely used for the diagnostic evaluation of patients with suspected PAVMs in the United States, although some HHT centers in Europe with expertise in MR angiography include it as part of their evaluation. Although MR angiography may show similar findings to those seen on CT, it is not as sensitive or specific diagnostically, and is more expensive; additionally, MR requires specialized expertise in the acquisition and interpretation of the images. However, MR angiography has the advantage of avoiding ionizing radiation. Diagnostic imaging findings on MR are discussed above. (See <a class="local">'Imaging findings'</a> above.)</p><p>Conventional spin-echo MR imaging has shown low sensitivity and specificity in the evaluation of PAVMs due to poor sensitivity to blood flow [<a href="#rid3">3</a>]. Despite the use of techniques to improve MR sensitivity to blood flow, including gradient-refocused echo MR imaging, phase contrast cine sequences, and contrast-enhanced MR angiography with multiplanar reconstruction, the sensitivity and specificity have generally remained lower than CT and pulmonary angiography [<a href="#rid88">88-92</a>]. However, a blinded study comparing contrast-enhanced MR imaging showed excellent sensitivity of 92 percent in the detection of PAVM with FAD of ≥2 mm when compared with CT; specificity depended on the experience of the reader (97 percent for an experienced reader versus 62 percent for a less experienced reader) [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/6976.html" rel="external">"Magnetic resonance imaging of the thorax"</a>.)</p><p class="headingAnchor" id="H534848604"><span class="h3">Routine laboratory tests</span><span class="headingEndMark"> — </span>Complete blood count and chemistries should be performed to look for anemia and polycythemia as well as for the detection of underlying chronic liver and chronic renal disease as potential etiologies for the presenting complaint. If not already performed, oxygen saturation (or occasionally arterial blood gas analysis) in the recumbent and standing positions should also be obtained to uncover underlying hypoxemia and orthodeoxia, respectively. (See <a class="local">'Platypnea and orthodeoxia'</a> above.)</p><p class="headingAnchor" id="H259353888"><span class="h3">Pulmonary function test</span><span class="headingEndMark"> — </span>Pulmonary function tests are often done for the investigation of the presenting complaint but are not specific or sensitive for the diagnosis of PAVMs. Standard spirometric indices are usually within normal limits in patients with PAVM. However, the diffusing capacity may be mildly elevated and resting minute ventilation is usually increased [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p class="headingAnchor" id="H259353908"><span class="h3">Pulmonary artery catheterization</span><span class="headingEndMark"> — </span>Pulmonary artery catheterization (PAC) may be performed in patients with PAVMs in whom pulmonary hypertension is suspected clinically (eg, loud pulmonic second heart sound, elevated jugular venous pressure, or leg edema). Details regarding the incidence of pulmonary hypertension and the value of PAC in predicting post embolization pulmonary artery pressures are discussed separately. (See <a class="local">'Features attributable to PAVM complications'</a> above and  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Initial diagnostic evaluation (noninvasive testing)'</a> and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Procedural complications'</a>.)</p><p class="headingAnchor" id="H462094277"><span class="h2">Evaluation for HHT</span><span class="headingEndMark"> — </span>In patients with suspected PAVMs without a known diagnosis of hereditary hemorrhagic telangiectasia (HHT), it is prudent to perform a thorough history and examination to look for clinical evidence of HHT (eg, personal or family history of epistaxis or arteriovenous malformations, and presence of mucocutaneous telangiectases). However, a lack of findings for HHT does not rule out the possibility for HHT [<a href="#rid30">30</a>]. The clinical manifestations and indications for genetic testing in patients with suspected HHT and their relatives are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1345.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p class="headingAnchor" id="H199144570"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>PAVMs are typically diagnosed by chest CT with the presence of shunt supported by contrast-enhanced pulmonary angiography. Typical findings include a well demarcated nodule with a well-defined feeding pulmonary artery and draining pulmonary vein. These and other classic radiographic features are discussed above. (See <a class="local">'Imaging findings'</a> above.)</p><p>A PAVM should always be suspected in a patient with a nodule and a history of cerebral infarct or abscess as well as in those with unexplained dyspnea, hypoxemia, hemoptysis, or hemothorax.</p><p class="headingAnchor" id="H462094752"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of PAVMs is wide and depends upon the presenting complaint. Although PAVMs are unusual causes of pulmonary nodules, dyspnea, hemoptysis, stroke, and cerebral abscess, they should be suspected when more common etiologies for these symptoms and signs are absent.</p><p class="bulletIndent1"><span class="glyph">●</span>For those who present with dyspnea, distinguishing features include platypnea and orthodeoxia, although these can also be found in hepatopulmonary syndrome, atrial septal defects (including patent foramen ovale), and other causes of shunt. Dyspnea from underlying cardiopulmonary disease should be evident on chest imaging and pulmonary function testing. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who present with hemoptysis, the cause may be related to nasal telangiectases, endobronchial telangiectases, or PAVM in the setting of hereditary hemorrhagic telangiectasia. Importantly, if PAVM is suspected, these lesions should not be randomly biopsied as significant bleeding can occur. (See  <a class="medical medical_review" href="/z/d/html/15663.html" rel="external">"Etiology of hemoptysis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with platypnea and orthodeoxia from hepatopulmonary syndrome should have evidence of underlying chronic liver disease, and if from atrial septal defect should have echocardiographic evidence of early right-to-left shunt. (See  <a class="medical medical_review" href="/z/d/html/8248.html" rel="external">"Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1418.html" rel="external">"Clinical manifestations and diagnosis of atrial septal defects in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CT imaging may reveal feeding arteries and veins that distinguish a PAVM from a primary or metastatic lesion of the lung and/or brain. (See  <a class="medical medical_review" href="/z/d/html/6986.html" rel="external">"Diagnostic evaluation of the incidental pulmonary nodule"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MRI of the brain will distinguish a cerebral infarct from an abscess, and cerebral AVM. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Confirming the diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis of anemia and polycythemia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">"Diagnostic approach to the patient with erythrocytosis/polycythemia"</a> and  <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a>.)</p><p></p><p class="headingAnchor" id="H862260687"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118986.html" rel="external">"Society guideline links: Hemoptysis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119057.html" rel="external">"Society guideline links: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)"</a>.)</p><p class="headingAnchor" id="H3674967"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Pulmonary arteriovenous malformations (PAVMs) are abnormal communications between pulmonary arteries and veins. They are uncommon, but they are an important consideration in the differential diagnosis of common pulmonary problems, including hypoxemia, pulmonary nodules, and hemoptysis. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/8267.html" rel="external">"Pulmonary arteriovenous malformations: Epidemiology, etiology, and pathology in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Approximately 40 percent of PAVMs are symptomatic and the remainder are found incidentally on chest imaging or during screening of patients with known or suspected hereditary hemorrhagic telangiectasia (HHT).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common presenting features are those attributable to the PAVM itself, usually dyspnea and hemoptysis  (<a class="graphic graphic_table graphicRef79966" href="/z/d/graphic/79966.html" rel="external">table 1</a>), as well as those attributable to underlying HHT, including epistaxis and mucocutaneous telangiectases  (<a class="graphic graphic_table graphicRef74593" href="/z/d/graphic/74593.html" rel="external">table 2</a>). In addition, PAVMs should always be suspected in patients who present with nodules and a history of a stroke or brain abscess, which are common complications of PAVMs. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conventional chest radiography  (<a class="graphic graphic_diagnosticimage graphicRef57484" href="/z/d/graphic/57484.html" rel="external">image 3</a>) and/or nonenhanced CT of the chest  (<a class="graphic graphic_diagnosticimage graphicRef127977" href="/z/d/graphic/127977.html" rel="external">image 6</a>) are abnormal in most patients who have symptoms due to PAVMs. While the typical appearances of PAVMs on chest radiography and CT are similar (ie, a nodule with a feeding artery and draining vein), in the era of CT evaluation of HHT patients and frequent use of CT in the general population, many patients present with atypical findings on chest CT  (<a class="graphic graphic_diagnosticimage graphicRef102806" href="/z/d/graphic/102806.html" rel="external">image 9</a>). Pulmonary angiography is not routinely used for the diagnostic evaluation of suspected PAVMs unless CT-identified lesions are potentially suitable for embolotherapy  (<a class="graphic graphic_diagnosticimage graphicRef102812" href="/z/d/graphic/102812.html" rel="external">image 11</a> and <a class="graphic graphic_diagnosticimage graphicRef102813" href="/z/d/graphic/102813.html" rel="external">image 13</a> and <a class="graphic graphic_diagnosticimage graphicRef100433" href="/z/d/graphic/100433.html" rel="external">image 14</a>). (See <a class="local">'Imaging findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – PAVMs should be suspected and a diagnostic evaluation initiated in individuals with one or more clinical features suggestive of PAVMs (eg, typical nodules on chest imaging), stigmata of right-to-left shunting (dyspnea, hypoxemia, cyanosis, cerebral embolism, brain abscess), unexplained hemoptysis, or hemothorax, as well as in patients with platypnea or orthodeoxia, and those with suspected, known, or a family history of HHT. (See <a class="local">'Indications for diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Shunt assessment</strong> – For most patients with suspected PAVMs in whom diagnostic testing is indicated, we suggest transthoracic contrast echocardiography (TTCE) as the initial test of choice to evaluate for the presence of a right-to-left shunt. Subsequent diagnostic testing with nonenhanced CT of the chest depends upon the identification and severity (ie, grade) of shunt found on TTCE  (<a class="graphic graphic_algorithm graphicRef102804" href="/z/d/graphic/102804.html" rel="external">algorithm 1</a>) (see <a class="local">'Diagnostic approach'</a> above and <a class="local">'Transthoracic contrast echocardiography'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients whose TTCE finds no right-to-left shunt (grade 0), we suggest no further evaluation for PAVMs, unless there are confounding factors that raise the clinical suspicion for PAVM such as unexplained hypoxemia, suspicious nodule on imaging, or evidence to suggest paradoxical embolization (eg, stroke).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients whose TTCE shows a grade 1 shunt, CT is not required due to the low risk of stroke and low likelihood of a treatable PAVM; yearly clinical observation and a repeat TTCE within five years is appropriate in this population so that small PAVMs that become symptomatic or have grown during the interval period will be detected. However, in patients with grade 1 shunt and a high clinical suspicion for treatable PAVM (eg, prior stroke), we prefer diagnostic testing with nonenhanced CT of the chest. (See <a class="local">'Computed tomography'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients whose TTCE shows a grade 2 or 3 shunt, we suggest nonenhanced CT of the chest. (See <a class="local">'Computed tomography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonenhanced CT of the chest</strong> – For patients with suspected PAVMs in whom CT scanning is indicated, we perform non-contrast-enhanced, multidetector, thin cut (ie, 1 to 2 mm collimation) CT of the chest; further testing is dependent upon the results of the scan  (<a class="graphic graphic_algorithm graphicRef102804" href="/z/d/graphic/102804.html" rel="external">algorithm 1</a>) (see <a class="local">'Computed tomography'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the CT scan shows one or more PAVMs with a feeding artery diameter (FAD) of ≥2 to 3 mm diameter, the patient should be referred for pulmonary angiography and potential embolotherapy. (See <a class="local">'Pulmonary angiography'</a> above and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Embolotherapy'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the CT scan shows PAVMs with a FAD &lt;2 mm, in most patients pulmonary angiography can be deferred and patients should undergo yearly clinical evaluation and CT in five years, though longer intervals can be considered. Pulmonary angiography may be performed in patients with symptoms suggestive of a treatable PAVM (eg, stroke).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the CT scan is negative and shunt is present on TTCE, microscopic PAVMs may be responsible and yearly clinical evaluation and CT in five years is prudent, though longer intervals can be considered. While the yield is low, pulmonary angiography is rarely performed in patients with symptoms suggestive of a possible treatable PAVM (eg, stroke).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the CT scan is indeterminate (eg, atypical features), further evaluation should be individualized. Some experts occasionally perform contrast pulmonary angiography in patients with high grade shunt and indeterminate CT scans in whom the clinical suspicion is high (eg, stroke). However, observation with follow-up TTCE and/or CT is also appropriate (eg, those with minimal symptoms and/or a low grade shunt).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary angiography</strong> – For patients with suspected PAVMs on CT, we perform contrast-enhanced pulmonary angiography to define the vascular anatomy of PAVMs that are identified on prior CT as potentially suitable for embolotherapy (ie, those with a feeding artery ≥2 to 3 mm in diameter). Although it is not routinely performed in patients for purely diagnostic reasons (eg, small asymptomatic lesions found on CT), pulmonary angiography can be performed in those with symptomatic lesions where uncertainty persists after other tests (eg, atypical lesions on CT with high-grade shunt of unidentified etiology). (See <a class="local">'Pulmonary angiography'</a> above and  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations", section on 'Embolotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and differential</strong> – PAVMs are typically diagnosed radiographically either by computed chest radiography or by contrast-enhanced pulmonary angiography. Typical findings include a well-demarcated nodule with a well-defined feeding pulmonary artery and draining pulmonary vein. The differential diagnosis of PAVMs is wide and depends upon the presenting complaint. Although PAVMs are unusual causes of pulmonary nodules, dyspnea, hemoptysis, stroke, and cerebral abscess, they should be suspected when more common etiologies for these symptoms and signs are absent. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3443012238"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James R Gossage, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Churton, T. Multiple aneurysms of the pulmonary artery. Br Med J 1897; 1:1223.</a></li><li><a class="nounderline abstract_t">SLOAN RD, COOLEY RN. Congenital pulmonary arteriovenous aneurysm. Am J Roentgenol Radium Ther Nucl Med 1953; 70:183.</a></li><li><a class="nounderline abstract_t">Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 1998; 158:643.</a></li><li><a class="nounderline abstract_t">Cottin V, Chinet T, Lavolé A, et al. Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. Medicine (Baltimore) 2007; 86:1.</a></li><li><a class="nounderline abstract_t">Pollak JS, Saluja S, Thabet A, et al. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol 2006; 17:35.</a></li><li><a class="nounderline abstract_t">Mager JJ, Overtoom TT, Blauw H, et al. Embolotherapy of pulmonary arteriovenous malformations: long-term results in 112 patients. J Vasc Interv Radiol 2004; 15:451.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63:259.</a></li><li><a class="nounderline abstract_t">Angriman F, Ferreyro BL, Wainstein EJ, Serra MM. Pulmonary arteriovenous malformations and embolic complications in patients with hereditary hemorrhagic telangiectasia. Arch Bronconeumol 2014; 50:301.</a></li><li><a class="nounderline abstract_t">Shin JH, Park SJ, Ko GY, et al. Embolotherapy for pulmonary arteriovenous malformations in patients without hereditary hemorrhagic telangiectasia. Korean J Radiol 2010; 11:312.</a></li><li><a class="nounderline abstract_t">Fuchizaki U, Miyamori H, Kitagawa S, et al. Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet 2003; 362:1490.</a></li><li><a class="nounderline abstract_t">Vase P, Holm M, Arendrup H. Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand 1985; 218:105.</a></li><li><a class="nounderline abstract_t">Plauchu H, de Chadarévian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32:291.</a></li><li><a class="nounderline abstract_t">Swanson KL, Prakash UB, Stanson AW. Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982-1997. Mayo Clin Proc 1999; 74:671.</a></li><li><a class="nounderline abstract_t">Dines DE, Arms RA, Bernatz PE, Gomes MR. Pulmonary arteriovenous fistulas. Mayo Clin Proc 1974; 49:460.</a></li><li><a class="nounderline abstract_t">STRINGER CJ, STANLEY AL, BATES RC, SUMMERS JE. Pulmonary arteriovenous fistula. Am J Surg 1955; 89:1054.</a></li><li><a class="nounderline abstract_t">Haitjema TJ, Overtoom TT, Westermann CJ, Lammers JW. Embolisation of pulmonary arteriovenous malformations: results and follow up in 32 patients. Thorax 1995; 50:719.</a></li><li><a class="nounderline abstract_t">Dines DE, Seward JB, Bernatz PE. Pulmonary arteriovenous fistulas. Mayo Clin Proc 1983; 58:176.</a></li><li><a class="nounderline abstract_t">Wong HH, Chan RP, Klatt R, Faughnan ME. Idiopathic pulmonary arteriovenous malformations: clinical and imaging characteristics. Eur Respir J 2011; 38:368.</a></li><li><a class="nounderline abstract_t">Albitar HAH, Segraves JM, Almodallal Y, et al. Pulmonary Arteriovenous Malformations in Non-hereditary Hemorrhagic Telangiectasia Patients: An 18-Year Retrospective Study. Lung 2020; 198:679.</a></li><li><a class="nounderline abstract_t">Kroon S, van den Heuvel DAF, Vos JA, et al. Idiopathic and hereditary haemorrhagic telangiectasia associated pulmonary arteriovenous malformations: comparison of clinical and radiographic characteristics. Clin Radiol 2021; 76:394.e1.</a></li><li><a class="nounderline abstract_t">Rozenberg D, Leek E, Faughnan ME. Prevalence and nature of dyspnea in patients with hereditary hemorrhagic telangiectasia (HHT). Respir Med 2015; 109:768.</a></li><li><a class="nounderline abstract_t">Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343:931.</a></li><li><a class="nounderline abstract_t">Gawecki F, Strangeways T, Amin A, et al. Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations. QJM 2019; 112:335.</a></li><li><a class="nounderline abstract_t">Santhirapala V, Chamali B, McKernan H, et al. Orthodeoxia and postural orthostatic tachycardia in patients with pulmonary arteriovenous malformations: a prospective 8-year series. Thorax 2014; 69:1046.</a></li><li><a class="nounderline abstract_t">White RI Jr, Lynch-Nyhan A, Terry P, et al. Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology 1988; 169:663.</a></li><li><a class="nounderline abstract_t">Dutton JA, Jackson JE, Hughes JM, et al. Pulmonary arteriovenous malformations: results of treatment with coil embolization in 53 patients. AJR Am J Roentgenol 1995; 165:1119.</a></li><li><a class="nounderline abstract_t">Terry PB, White RI Jr, Barth KH, et al. Pulmonary arteriovenous malformations. Physiologic observations and results of therapeutic balloon embolization. N Engl J Med 1983; 308:1197.</a></li><li><a class="nounderline abstract_t">Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995; 122:521.</a></li><li><a class="nounderline abstract_t">Faughnan ME, Lui YW, Wirth JA, et al. Diffuse pulmonary arteriovenous malformations: characteristics and prognosis. Chest 2000; 117:31.</a></li><li><a class="nounderline abstract_t">Anderson E, Sharma L, Alsafi A, Shovlin CL. Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia. Thorax 2022; 77:628.</a></li><li><a class="nounderline abstract_t">Moussouttas M, Fayad P, Rosenblatt M, et al. Pulmonary arteriovenous malformations: cerebral ischemia and neurologic manifestations. Neurology 2000; 55:959.</a></li><li><a class="nounderline abstract_t">Maher CO, Piepgras DG, Brown RD Jr, et al. Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 2001; 32:877.</a></li><li><a class="nounderline abstract_t">Velthuis S, Buscarini E, van Gent MW, et al. Grade of pulmonary right-to-left shunt on contrast echocardiography and cerebral complications: a striking association. Chest 2013; 144:542.</a></li><li><a class="nounderline abstract_t">Ference BA, Shannon TM, White RI Jr, et al. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994; 106:1387.</a></li><li><a class="nounderline abstract_t">Gershon AS, Faughnan ME, Chon KS, et al. Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy. Chest 2001; 119:470.</a></li><li><a class="nounderline abstract_t">Sluiter-Eringa H, Orie NG, Sluiter HJ. Pulmonary arteriovenous fistula. Diagnosis and prognosis in noncomplainant patients. Am Rev Respir Dis 1969; 100:177.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Tighe HC, Davies RJ, et al. Embolisation of pulmonary arteriovenous malformations: no consistent effect on pulmonary artery pressure. Eur Respir J 2008; 32:162.</a></li><li><a class="nounderline abstract_t">Sperling DC, Cheitlin M, Sullivan RW, Smith A. Pulmonary arteriovenous fistulas with pulmonary hypertension. Chest 1977; 71:753.</a></li><li><a class="nounderline abstract_t">Chizinga M, Rudkovskaia AA, Henderson K, et al. Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations. Am J Respir Crit Care Med 2017; 196:1353.</a></li><li><a class="nounderline abstract_t">Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003; 40:865.</a></li><li><a class="nounderline abstract_t">Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:325.</a></li><li><a class="nounderline abstract_t">Abdalla SA, Gallione CJ, Barst RJ, et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 2004; 23:373.</a></li><li><a class="nounderline abstract_t">Papagiannis J, Apostolopoulou S, Sarris G, Rammos S. Diagnosis and management of pulmonary arteriovenous malformations. Images Paediatr Cardiol 2002; 4:33.</a></li><li><a class="nounderline abstract_t">Rodan BA, Goodwin JD, Chen JT, Ravin CE. Worsening pulmonary hypertension after resection of arteriovenous fistula. AJR Am J Roentgenol 1981; 137:864.</a></li><li><a class="nounderline abstract_t">Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.</a></li><li><a class="nounderline abstract_t">BOSHER LH Jr, BLAKE DA, BYRD BR. An analysis of the pathologic anatomy of pulmonary arteriovenous aneurysms with particular reference to the applicability of local excision. Surgery 1959; 45:91.</a></li><li><a class="nounderline abstract_t">Jaskolka J, Wu L, Chan RP, Faughnan ME. Imaging of hereditary hemorrhagic telangiectasia. AJR Am J Roentgenol 2004; 183:307.</a></li><li><a class="nounderline abstract_t">Remy J, Remy-Jardin M, Wattinne L, Deffontaines C. Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology 1992; 182:809.</a></li><li><a class="nounderline abstract_t">Remy J, Remy-Jardin M, Giraud F, Wattinne L. Angioarchitecture of pulmonary arteriovenous malformations: clinical utility of three-dimensional helical CT. Radiology 1994; 191:657.</a></li><li><a class="nounderline abstract_t">Lee HN, Hyun D. Pulmonary Arteriovenous Malformation and Its Vascular Mimickers. Korean J Radiol 2022; 23:202.</a></li><li><a class="nounderline abstract_t">Hanley M, Ahmed O, Chandra A, et al. ACR Appropriateness Criteria Clinically Suspected Pulmonary Arteriovenous Malformation. J Am Coll Radiol 2016; 13:796.</a></li><li><a class="nounderline abstract_t">Whyte MK, Hughes JM, Jackson JE, et al. Cardiopulmonary response to exercise in patients with intrapulmonary vascular shunts. J Appl Physiol (1985) 1993; 75:321.</a></li><li><a class="nounderline abstract_t">Chilvers ER, Whyte MK, Jackson JE, et al. Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left shunt, and arterial oxygenation in patients with pulmonary arteriovenous malformations. Am Rev Respir Dis 1990; 142:420.</a></li><li><a class="nounderline abstract_t">Murphy J, Pierucci P, Chyun D, et al. Results of exercise stress testing in patients with diffuse pulmonary arteriovenous malformations. Pediatr Cardiol 2009; 30:978.</a></li><li><a class="nounderline abstract_t">Haitjema T, Disch F, Overtoom TT, et al. Screening family members of patients with hereditary hemorrhagic telangiectasia. Am J Med 1995; 99:519.</a></li><li><a class="nounderline abstract_t">Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169:994.</a></li><li><a class="nounderline abstract_t">van Gent MW, Post MC, Snijder RJ, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010; 138:833.</a></li><li><a class="nounderline abstract_t">McAllister KA, Lennon F, Bowles-Biesecker B, et al. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J Med Genet 1994; 31:927.</a></li><li><a class="nounderline abstract_t">Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48:73.</a></li><li><a class="nounderline abstract_t">Barzilai B, Waggoner AD, Spessert C, et al. Two-dimensional contrast echocardiography in the detection and follow-up of congenital pulmonary arteriovenous malformations. Am J Cardiol 1991; 68:1507.</a></li><li><a class="nounderline abstract_t">Gossage JR. Role of contrast echocardiography in screening for pulmonary arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Chest 2010; 138:769.</a></li><li><a class="nounderline abstract_t">Zukotynski K, Chan RP, Chow CM, et al. Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest 2007; 132:18.</a></li><li><a class="nounderline abstract_t">Gazzaniga P, Buscarini E, Leandro G, et al. Contrast echocardiography for pulmonary arteriovenous malformations screening: does any bubble matter? Eur J Echocardiogr 2009; 10:513.</a></li><li><a class="nounderline abstract_t">Nanthakumar K, Graham AT, Robinson TI, et al. Contrast echocardiography for detection of pulmonary arteriovenous malformations. Am Heart J 2001; 141:243.</a></li><li><a class="nounderline abstract_t">Velthuis S, Buscarini E, Gossage JR, et al. Clinical implications of pulmonary shunting on saline contrast echocardiography. J Am Soc Echocardiogr 2015; 28:255.</a></li><li><a class="nounderline abstract_t">Oxhøj H, Kjeldsen AD, Nielsen G. Screening for pulmonary arteriovenous malformations: contrast echocardiography versus pulse oximetry. Scand Cardiovasc J 2000; 34:281.</a></li><li><a class="nounderline abstract_t">Andersen PE, Kjeldsen AD, Oxhøj H, et al. Embolotherapy for pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Acta Radiol 1998; 39:723.</a></li><li><a class="nounderline abstract_t">Lee WL, Graham AF, Pugash RA, et al. Contrast echocardiography remains positive after treatment of pulmonary arteriovenous malformations. Chest 2003; 123:351.</a></li><li><a class="nounderline abstract_t">Oliveira GH, Seward JB, Cortese DA, Dines DE. Contrast transesophageal echocardiography in the diagnosis and localization of diffuse pulmonary telangiectasias. Chest 2000; 118:557.</a></li><li><a class="nounderline abstract_t">Shub C, Tajik AJ, Seward JB, Dines DE. Detecting intrapulmonary right-to-left shunt with contrast echocardiography. Observations in a patient with diffuse pulmonary arteriovenous fistulas. Mayo Clin Proc 1976; 51:81.</a></li><li><a class="nounderline abstract_t">Seward JB, Tajik AJ, Spangler JG, Ritter DG. Echocardiographic contrast studies: initial experience. Mayo Clin Proc 1975; 50:163.</a></li><li><a class="nounderline abstract_t">van Gent MW, Post MC, Snijder RJ, et al. Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy? Chest 2009; 135:1288.</a></li><li><a class="nounderline abstract_t">Parra JA, Bueno J, Zarauza J, et al. Graded contrast echocardiography in pulmonary arteriovenous malformations. Eur Respir J 2010; 35:1279.</a></li><li><a class="nounderline abstract_t">Velthuis S, Buscarini E, Mager JJ, et al. Predicting the size of pulmonary arteriovenous malformations on chest computed tomography: a role for transthoracic contrast echocardiography. Eur Respir J 2014; 44:150.</a></li><li><a class="nounderline abstract_t">Vorselaars VM, Velthuis S, Snijder RJ, et al. Follow-up of pulmonary right-to-left shunt in hereditary haemorrhagic telangiectasia. Eur Respir J 2016; 47:1750.</a></li><li><a class="nounderline abstract_t">Brinjikji W, Latino GA, Parvinian A, et al. Diagnostic Yield of Rescreening Adults for Pulmonary Arteriovenous Malformations. J Vasc Interv Radiol 2019; 30:1982.</a></li><li><a class="nounderline abstract_t">Kjeldsen AD, Oxhøj H, Andersen PE, et al. Pulmonary arteriovenous malformations: screening procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia. Chest 1999; 116:432.</a></li><li><a class="nounderline abstract_t">Kjeldsen AD, Vase P, Oxhøj H. Hereditary hemorrhagic telangiectasia. N Engl J Med 1996; 334:331.</a></li><li><a class="nounderline abstract_t">Whyte MK, Peters AM, Hughes JM, et al. Quantification of right to left shunt at rest and during exercise in patients with pulmonary arteriovenous malformations. Thorax 1992; 47:790.</a></li><li><a class="nounderline abstract_t">Thompson RD, Jackson J, Peters AM, et al. Sensitivity and specificity of radioisotope right-left shunt measurements and pulse oximetry for the early detection of pulmonary arteriovenous malformations. Chest 1999; 115:109.</a></li><li><a class="nounderline abstract_t">Ueki J, Hughes JM, Peters AM, et al. Oxygen and 99mTc-MAA shunt estimations in patients with pulmonary arteriovenous malformations: effects of changes in posture and lung volume. Thorax 1994; 49:327.</a></li><li><a class="nounderline abstract_t">Chick JFB, Reddy SN, Pyeritz RE, Trerotola SO. A Survey of Pulmonary Arteriovenous Malformation Screening, Management, and Follow-Up in Hereditary Hemorrhagic Telangiectasia Centers of Excellence. Cardiovasc Intervent Radiol 2017; 40:1003.</a></li><li><a class="nounderline abstract_t">Curnes NR, Desjardins B, Pyeritz R, et al. Lack of Growth of Small (≤2 mm Feeding Artery) Untreated Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia. J Vasc Interv Radiol 2019; 30:1259.</a></li><li><a class="nounderline abstract_t">Ryan DJ, O'Connor TM, Murphy MM, Brady AP. Follow-up interval for small untreated pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Clin Radiol 2017; 72:236.</a></li><li><a class="nounderline abstract_t">Godwin JD, Webb WR. Dynamic computed tomography in the evaluation of vascular lung lesions. Radiology 1981; 138:629.</a></li><li><a class="nounderline abstract_t">White RI Jr, Mitchell SE, Barth KH, et al. Angioarchitecture of pulmonary arteriovenous malformations: an important consideration before embolotherapy. AJR Am J Roentgenol 1983; 140:681.</a></li><li><a class="nounderline abstract_t">White RI Jr, Pollak JS, Wirth JA. Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. J Vasc Interv Radiol 1996; 7:787.</a></li><li><a class="nounderline abstract_t">Silverman JM, Julien PJ, Herfkens RJ, Pelc NJ. Magnetic resonance imaging evaluation of pulmonary vascular malformations. Chest 1994; 106:1333.</a></li><li><a class="nounderline abstract_t">Ohno Y, Hatabu H, Takenaka D, et al. Contrast-enhanced MR perfusion imaging and MR angiography: utility for management of pulmonary arteriovenous malformations for embolotherapy. Eur J Radiol 2002; 41:136.</a></li><li><a class="nounderline abstract_t">Khalil A, Farres MT, Mangiapan G, et al. Pulmonary arteriovenous malformations. Chest 2000; 117:1399.</a></li><li><a class="nounderline abstract_t">Schneider G, Uder M, Koehler M, et al. MR angiography for detection of pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. AJR Am J Roentgenol 2008; 190:892.</a></li><li><a class="nounderline abstract_t">Hamamoto K, Matsuura K, Chiba E, et al. Feasibility of Non-contrast-enhanced MR Angiography Using the Time-SLIP Technique for the Assessment of Pulmonary Arteriovenous Malformation. Magn Reson Med Sci 2016; 15:253.</a></li><li><a class="nounderline abstract_t">Van den Heuvel DAF, Post MC, Koot W, et al. Comparison of Contrast Enhanced Magnetic Resonance Angiography to Computed Tomography in Detecting Pulmonary Arteriovenous Malformations. J Clin Med 2020; 9.</a></li></ol></div><div id="topicVersionRevision">Topic 8268 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Multiple aneurysms of the pulmonary artery</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13065567" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Congenital pulmonary arteriovenous aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9700146" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary arteriovenous malformations. A state of the art review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17220751" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415131" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126654" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Embolotherapy of pulmonary arteriovenous malformations: long-term results in 112 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981912" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24629762" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pulmonary arteriovenous malformations and embolic complications in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20461185" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Embolotherapy for pulmonary arteriovenous malformations in patients without hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14602446" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4050544" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729347" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405695" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982-1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4834927" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pulmonary arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14361892" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pulmonary arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7570404" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Embolisation of pulmonary arteriovenous malformations: results and follow up in 32 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6219255" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177836" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Idiopathic pulmonary arteriovenous malformations: clinical and imaging characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32648120" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulmonary Arteriovenous Malformations in Non-hereditary Hemorrhagic Telangiectasia Patients: An 18-Year Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33648759" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Idiopathic and hereditary haemorrhagic telangiectasia associated pulmonary arteriovenous malformations: comparison of clinical and radiographic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25940942" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevalence and nature of dyspnea in patients with hereditary hemorrhagic telangiectasia (HHT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11006369" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Liver disease in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657990" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24713588" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Orthodeoxia and postural orthostatic tachycardia in patients with pulmonary arteriovenous malformations: a prospective 8-year series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3186989" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7572487" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pulmonary arteriovenous malformations: results of treatment with coil embolization in 53 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6405268" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulmonary arteriovenous malformations. Physiologic observations and results of therapeutic balloon embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872588" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The hepatopulmonary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631195" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diffuse pulmonary arteriovenous malformations: characteristics and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35165143" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061251" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary arteriovenous malformations: cerebral ischemia and neurologic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283386" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429940" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Grade of pulmonary right-to-left shunt on contrast echocardiography and cerebral complications: a striking association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956388" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171725" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4896450" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pulmonary arteriovenous fistula. Diagnosis and prognosis in noncomplainant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385173" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Embolisation of pulmonary arteriovenous malformations: no consistent effect on pulmonary artery pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/862444" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pulmonary arteriovenous fistulas with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28375020" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684682" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11484689" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15065824" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22368610" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diagnosis and management of pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6974987" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Worsening pulmonary hypertension after resection of arteriovenous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10413726" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13624986" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An analysis of the pathologic anatomy of pulmonary arteriovenous aneurysms with particular reference to the applicability of local excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269017" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Imaging of hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535899" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8184042" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Angioarchitecture of pulmonary arteriovenous malformations: clinical utility of three-dimensional helical CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35029077" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pulmonary Arteriovenous Malformation and Its Vascular Mimickers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27209598" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : ACR Appropriateness Criteria Clinically Suspected Pulmonary Arteriovenous Malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8376281" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cardiopulmonary response to exercise in patients with intrapulmonary vascular shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2382905" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left shunt, and arterial oxygenation in patients with pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636485" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Results of exercise stress testing in patients with diffuse pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7485210" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Screening family members of patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742303" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154077" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891374" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553198" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1746435" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Two-dimensional contrast echocardiography in the detection and follow-up of congenital pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923794" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Role of contrast echocardiography in screening for pulmonary arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17317734" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091794" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Contrast echocardiography for pulmonary arteriovenous malformations screening: does any bubble matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174338" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Contrast echocardiography for detection of pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623000" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical implications of pulmonary shunting on saline contrast echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10935775" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Screening for pulmonary arteriovenous malformations: contrast echocardiography versus pulse oximetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817050" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Embolotherapy for pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576351" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Contrast echocardiography remains positive after treatment of pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10936159" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Contrast transesophageal echocardiography in the diagnosis and localization of diffuse pulmonary telangiectasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1246162" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Detecting intrapulmonary right-to-left shunt with contrast echocardiography. Observations in a patient with diffuse pulmonary arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1123933" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Echocardiographic contrast studies: initial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118272" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996192" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Graded contrast echocardiography in pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603816" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Predicting the size of pulmonary arteriovenous malformations on chest computed tomography: a role for transthoracic contrast echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26965291" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Follow-up of pulmonary right-to-left shunt in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31530490" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Diagnostic Yield of Rescreening Adults for Pulmonary Arteriovenous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10453873" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pulmonary arteriovenous malformations: screening procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532039" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1481178" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Quantification of right to left shunt at rest and during exercise in patients with pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925070" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sensitivity and specificity of radioisotope right-left shunt measurements and pulse oximetry for the early detection of pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8202901" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Oxygen and 99mTc-MAA shunt estimations in patients with pulmonary arteriovenous malformations: effects of changes in posture and lung volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28188364" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A Survey of Pulmonary Arteriovenous Malformation Screening, Management, and Follow-Up in Hereditary Hemorrhagic Telangiectasia Centers of Excellence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31255500" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Lack of Growth of Small (≤2 mm Feeding Artery) Untreated Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28040200" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Follow-up interval for small untreated pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7465840" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Dynamic computed tomography in the evaluation of vascular lung lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6601370" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Angioarchitecture of pulmonary arteriovenous malformations: an important consideration before embolotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8951745" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956380" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Magnetic resonance imaging evaluation of pulmonary vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809543" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Contrast-enhanced MR perfusion imaging and MR angiography: utility for management of pulmonary arteriovenous malformations for embolotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807828" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pulmonary arteriovenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356434" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : MR angiography for detection of pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26841853" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Feasibility of Non-contrast-enhanced MR Angiography Using the Time-SLIP Technique for the Assessment of Pulmonary Arteriovenous Malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33202566" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Comparison of Contrast Enhanced Magnetic Resonance Angiography to Computed Tomography in Detecting Pulmonary Arteriovenous Malformations.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
